Tag: Gilead Science’s MAA for Hepa-C drug anticipates approval

Gilead Science’s MAA for Hepa-C drug anticipates approval

December 7, 2015

US biopharmaceutical firm Gilead Sciences, Inc announced that its Marketing Authorization Application (MAA) for an investigational, once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg and velpatasvir (VEL) 100 mg, an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic hepatitis C virus (HCV) infection, has been fully validated and is […]

Continue Reading